Eli Lilly and Company at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Eli Lilly and Company at ASHG 2026 in Montréal: 3 presentations (3 posters).

Organization	ASHG 2026 Attendance
Eli Lilly and Company Boston, Massachusetts	1 Senior Advisor, Genomics · 1 Director of Neurodegeneration and Genetic Medicines · 1 Vice President - Obesity and Complications · 1 other presenter
lilly.com\|LinkedIn Public company~51,168 people Lilly develops and sells prescription medicines for patients across cardiometabolic health, immunology, neuroscience, and cancer. Agrees to acquire AtaiBeckley for neuroscience expansion (2026-07) › Agrees to acquire AtaiBeckley for neuroscience expansion · 2026-07-16 “today announced a definitive agreement for Lilly to acquire AtaiBeckley.” Announces three acquisitions to build infectious disease portfolio · 2026-05-26 “today announced agreements to acquire three companies, Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc.” Agrees to acquire Centessa for sleep-wake medicines · 2026-03-31 “today announced a definitive agreement for Lilly to acquire Centessa.” Source: company newsroom Q2 2026 revenue $23.0bn, up 48% › Q2 2026 revenue was $23.0 billion, up 48% year over year; full-year 2026 revenue guidance was $85.0 billion to $87.0 billion. · 2026-08-05 “Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.” Source: results release	Poster Wed Oct 21 2:30 pm Part of Complex Traits and Polygenic Disorders Poster Wednesday Session Circulating proteomics associated with reductions in liver fat and visceral and subcutaneous adiposity in adults with obesity and MASLD with retatrutide treatment Exhibit & Poster Hall · Board 8345W Complex diseasesComplex traitsMetabolic disorderProteomics Poster Wed Oct 21 2:30 pm Part of Genetic Therapies and Precision Medicine Poster Wednesday Session Genome-wide association analysis in cognitively unimpaired Alzheimer’s disease reveals novel loci associating with rate of clinical progression in the A4 clinical trial Exhibit & Poster Hall · Board 5012W Alzheimer’s diseaseClinical geneticsIdentification of disease genesTranslational studies and preclinical trials Poster Fri Oct 23 2:30 pm Part of Pharmacogenomics Poster Friday Session Tirzepatide and semaglutide induce differential plasma proteomic signatures in adults with obesity: an exploratory analysis of SURMOUNT-5 Exhibit & Poster Hall · Board 2019F ProteomicsPharmacogenomicsObesityMolecular therapeutics Attendee Named in a LinkedIn post about ASHG 2026View post on LinkedInPosted Aug 10, 2026

Organization

ASHG 2026 Attendance

Boston, Massachusetts

1 Senior Advisor, Genomics · 1 Director of Neurodegeneration and Genetic Medicines · 1 Vice President - Obesity and Complications · 1 other presenter

lilly.com|LinkedIn

Public company~51,168 people

Lilly develops and sells prescription medicines for patients across cardiometabolic health, immunology, neuroscience, and cancer.

Agrees to acquire AtaiBeckley for neuroscience expansion (2026-07)

›

Agrees to acquire AtaiBeckley for neuroscience expansion · 2026-07-16

“today announced a definitive agreement for Lilly to acquire AtaiBeckley.”

Announces three acquisitions to build infectious disease portfolio · 2026-05-26

“today announced agreements to acquire three companies, Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc.”

Agrees to acquire Centessa for sleep-wake medicines · 2026-03-31

“today announced a definitive agreement for Lilly to acquire Centessa.”

Source: company newsroom

Q2 2026 revenue $23.0bn, up 48%

›

Q2 2026 revenue was $23.0 billion, up 48% year over year; full-year 2026 revenue guidance was $85.0 billion to $87.0 billion. · 2026-08-05

“Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.”

Source: results release

Poster

Wed Oct 21
2:30 pm

Part of Complex Traits and Polygenic Disorders Poster Wednesday Session

Circulating proteomics associated with reductions in liver fat and visceral and subcutaneous adiposity in adults with obesity and MASLD with retatrutide treatment

Exhibit & Poster Hall · Board 8345W

Complex diseasesComplex traitsMetabolic disorderProteomics

Poster

Wed Oct 21
2:30 pm

Part of Genetic Therapies and Precision Medicine Poster Wednesday Session

Genome-wide association analysis in cognitively unimpaired Alzheimer’s disease reveals novel loci associating with rate of clinical progression in the A4 clinical trial

Exhibit & Poster Hall · Board 5012W

Alzheimer’s diseaseClinical geneticsIdentification of disease genesTranslational studies and preclinical trials

Poster

Fri Oct 23
2:30 pm

Part of Pharmacogenomics Poster Friday Session

Tirzepatide and semaglutide induce differential plasma proteomic signatures in adults with obesity: an exploratory analysis of SURMOUNT-5

Exhibit & Poster Hall · Board 2019F

ProteomicsPharmacogenomicsObesityMolecular therapeutics

Attendee

Named in a LinkedIn post about ASHG 2026View post on LinkedInPosted Aug 10, 2026

Instantly find 20 buyers from Eli Lilly and Company

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction